Aduhelm is supposed to be a treatment for alzheimers. It's about $28k per year.
The Medicare Trustees projected in August 2021 that the standard Part B premium for 2022 would be $158.50, which did not account for the costs of Aduhelm. In November, CMS raised the Part B premium to $170.10, in anticipation of the increased spending from Aduhelm.
However it hasn't been shown to .
There appears to be little evidence on the likelihood of Aduhelm’s action translating into meaningful benefits for patients with Alzheimer’s.
Because it's super expensive and likely worthless, medicare decided to .
Medicare will cover it only for people who receive it as participants in a clinical trial.
The FDA approved this snake oil despite 10 of 11 members of their advisory panel voting against approval.
Aduhelm is supposed to be a treatment for alzheimers. It's about $28k per year.
> The Medicare Trustees projected in August 2021 that the standard Part B premium for 2022 would be $158.50, which did not account for the costs of Aduhelm. In November, CMS raised the Part B premium to $170.10, in anticipation of the increased spending from Aduhelm.
However it hasn't been shown to [actually help patients](https://themedicinemaker.com/business-regulation/addressing-the-aduhelm-controversy).
> There appears to be little evidence on the likelihood of Aduhelm’s action translating into meaningful benefits for patients with Alzheimer’s.
Because it's super expensive and likely worthless, medicare decided to [limit who can receive it](https://archive.ph/UJpCS).
> Medicare will cover it only for people who receive it as participants in a clinical trial.
The FDA approved this snake oil despite 10 of 11 members of their advisory panel voting against approval.
(post is archived)